Dipeptidyl Peptidase-4 Inhibition and the Treatment of Type 2 Diabetes-Reference-Cited by-同舟云学术

Dipeptidyl Peptidase-4 Inhibition and the Treatment of Type 2 Diabetes

Published:2007-06-01 Issue:6 Volume:30 Page:1335-1343
ISSN:0149-5992
Container-title:Diabetes Care
language:en
Short-container-title:

Author:

Drucker Daniel J.¹

Affiliation:

1. From the Department of Medicine, Banting and Best Diabetes Centre, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, University of Toronto, Ontario, Canada

Publisher

American Diabetes Association

Subject

Advanced and Specialized Nursing,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://diabetesjournals.org/care/article-pdf/30/6/1335/597524/zdc00607001335.pdf

Reference84 articles.

1. Lambeir AM, Durinx C, Scharpe S, De Meester I: Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci 40: 209–294, 2003

2. Abbott CA, Baker E, Sutherland GR, McCaughan GW: Genomic organization, exact localization, and tissue expression of the human CD26 (dipeptidyl peptidase IV) gene. Immunogenetics 40:331–338, 1994

3. Durinx C, Lambeir AM, Bosmans E, Falmagne JB, Berghmans R, Haemers A, Scharpe S, De Meester I: Molecular characterization of dipeptidyl peptidase activity in serum: soluble CD26/dipeptidyl peptidase IV is responsible for the release of X-Pro dipeptides. Eur J Biochem 267:5608–5613, 2000

4. Ikushima H, Munakata Y, Iwata S, Ohnuma K, Kobayashi S, Dang NH, Morimoto C: Soluble CD26/dipeptidyl peptidase IV enhances transendothelial migration via its interaction with mannose 6-phosphate/insulin-like growth factor II receptor. Cell Immunol 215:106–110, 2002

5. Gorrell MD: Dipeptidyl peptidase IV and related enzymes in cell biology and liver disorders. Clin Sci (Lond) 108:277–292, 2005

Cited by 326 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adipose tissue in older individuals: a contributing factor to sarcopenia;Metabolism;2024-11

2. Sitagliptin is a time-tested leading drug in the treatment of type 2 diabetes;Meditsinskiy sovet = Medical Council;2024-09-02

3. Diabetic liver-enriched secretory dipeptidyl peptidase 4 (DPP4) fuels gut inflammation via attenuation of autophagy;2024-08-08

4. Role and mechanism of specialized pro-resolving mediators in obesity-associated insulin resistance;Lipids in Health and Disease;2024-07-30

5. Role for DPP4 inhibitor therapy in cystic fibrosis related diabetes: A single centre experience;Journal of Cystic Fibrosis;2024-07